Skip to content

Alastair Garfield, Chief Scientific Officer at Rhythm Pharmaceuticals, sold RYTM on Aug 13, 2026

Data as of Oct 16

▼ SELL$182K1,556 shares at $117.08Alastair Garfield Chief Scientific OfficerRYTM Rhythm Pharmaceuticals, Inc.
Watch RYTM
Traded
Aug 13, 2026
Disclosed
Aug 17, 2026
Filed
4 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Alastair Garfield, Chief Scientific Officer at Rhythm Pharmaceuticals, sold RYTM on Aug 13, 2026TRADEDDISCLOSED
RYTMSimilar stocks (XLV — its sector index fund), rebased to RYTM's price on the disclosure day
RYTM since disclosure
−25.4%
after the sale
Similar stocks (XLV) since disclosure
+5.8%
XLV — its sector index fund

Change in closing price from Aug 17, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLAlastair Garfield Chief Scientific OfficerRYTM Rhythm Pharmaceuticals, Inc.$402Kdisclosed Aug 17 · filed 4 days after the trade
  2. ▼ SELLAlastair Garfield Chief Scientific OfficerRYTM Rhythm Pharmaceuticals, Inc.$233Kdisclosed Aug 17 · filed 4 days after the trade
  3. ▼ SELLAlastair Garfield Chief Scientific OfficerRYTM Rhythm Pharmaceuticals, Inc.$95.3Kdisclosed Aug 17 · filed 4 days after the trade

See every trade on RYTM →